Background and objective: A characteristic feature of asthma is hypertrophied airway smooth muscle, responsible for bronchoconstriction. This is the target of bronchial thermoplasty (BT). It is known that with increasing time and severity some patients develop remodelled airways with fixed airflow obstruction. The question arises whether these patients will still respond to BT. Methods: Forty-nine consecutive severe asthmatic patients were prospectively evaluated at baseline and then 6 months after BT. The characteristics recorded included medication usage, exacerbation history, spirometry and the Asthma Control Questionnaire 5-Item Version score (ACQ-5). Seven patients were excluded as they did not demonstrate airflow obstruction at baseline (forced expiratory ratio (forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC)) < 70%). The remaining 42 patients were divided into two cohorts based on their response to bronchodilator. Eighteen patients in whom the FEV 1 improved by at least 12% and 200 mL following bronchodilator were allocated to Group 1 (reversible). The remaining patients were allocated to Group 2 (fixed). The outcomes following BT in these two groups were then compared. Results: The patient age was 57.2 AE 12.4 years, the ACQ-5 was 3.2 AE 1.0 and the FEV 1 56.0 AE 16.4% predicted. At baseline, the patient cohorts were very similar, save for the response to bronchodilator, which was 28.1 AE 12.5% in Group 1 and 4.1 AE 5.3% in Group 2. Both groups responded to BT equally well, with significant improvements in ACQ-5, salbutamol usage, exacerbation frequency and the weaning of oral corticosteroids. Conclusion: In patients with severe asthma, the presence or absence of variable airflow obstruction as
INTRODUCTION
Asthma is classically defined as a disease of variable airflow obstruction. 1 As a result, most randomized clinical trials of therapies for asthma require the demonstration at study entry of at least a 12% improvement in forced expiratory volume in 1 s (FEV 1 ) following administration of salbutamol, as well as 200 mL change. 2 However, with increasing asthma duration and severity, remodelling of the airway is known to occur in some patients, with subsequent loss of acute responsiveness to bronchodilator. 3, 4 Such patients are poorly represented in clinical trials and, hence, their optimal treatment is less clear. 1 In the Australian healthcare system for example, the demonstration of bronchodilator reversibility is a mandatory prerequisite in order to access funded biological therapies for asthma.
SUMMARY AT A GLANCE
This study, in patients with severe asthma, compares the outcomes from bronchial thermoplasty (BT) in patients with fixed airflow obstruction, with patients with bronchodilator reversibility. The study concludes that both groups of patients benefit equally well from this therapy and that bronchodilator reversibility need not be a selection criterion for BT.
One of the hallmarks of the asthmatic airway is hypertrophy of the airway smooth muscle. 7 This smooth muscle layer is the effector of bronchoconstriction and is targeted by bronchial thermoplasty (BT), which uses radiofrequency thermal energy to induce atrophy of the airway smooth muscle. 8, 9 Therefore, proceduralists are frequently asked whether the demonstration of responsiveness to bronchodilator is a prerequisite for success with BT, or, put another way: Can patients with 'fixed' airflow obstruction due to asthma also gain benefit from BT? However, in previous studies of BT, the presence of bronchodilator reversibility has not been a mandatory inclusion criterion. 10 This current study aims to address this question by comparing the responses to BT in a cohort of asthmatic patients with fixed airflow obstruction at baseline, with a cohort of classical asthmatic patients with bronchodilator reversibility.
METHODS

Participants
The clinical data of consecutive patients selected for BT at three Australian university teaching hospitals were prospectively collated between June 2014 and June 2017. Participants were referred to an interventional pulmonologist for BT by their treating respiratory physician if they had frequent symptoms despite optimized asthma therapy including high-dose inhaled corticosteroids and two long-acting bronchodilators. The baseline characteristics that were recorded included age, gender, body mass index (BMI), medication usage, exacerbation history and the disease-specific quality of life tool, the Asthma Control Questionnaire 5-Item Version score (ACQ-5). The ACQ-5 is a well-validated instrument for the assessment of symptoms in asthma, is known to be stable over time and yet sensitive to change. 11 Baseline measurements of total serum IgE and blood eosinophil levels were also recorded. Approval to collate and audit data as part of quality assurance was provided by the Human Research Ethics Committees at Peninsula Health and at Macquarie University Hospital. All participants provided informed consent for treatment and data collection. Specific permission to use the ACQ-5 in this project was granted by its author, Elizabeth Juniper.
Lung function measurement
Lung function testing was conducted in accredited respiratory laboratories by experienced scientific staff, and according to European Respiratory Society/American Thoracic Society (ERS/ATS) standards. 12 Instrument calibration was performed immediately prior to testing. All tests were performed in the morning, and prior to the administration of all bronchodilators that day. Tests were conducted in the seated position using the Jaeger Masterscreen Body (Carefusion, Hoechberg, Germany). For spirometry, at least three acceptable manoeuvres were obtained. Post-bronchodilator spirometry was performed between 10 and 20 min after the administration of 400 μg salbutamol. The singlebreath diffusing capacity for carbon monoxide (DL CO ) was also tested, and the gas transfer per lung unit (KCO) was calculated and expressed as a percentage of predicted. The predicted equations used were Quanjer 13 for spirometry, and ECCS 1993 14 for DL CO . Testing was conducted in the 4 weeks prior to BT being undertaken, and then 6 months after the final BT procedure.
Cohort assignment
For the purposes of this study, airflow obstruction was defined by the presence of a forced expiratory ratio (FEV 1 /forced vital capacity(FVC)) of less than 70% on baseline prebronchodilator spirometry. 15 Patients who did not exhibit airflow obstruction by spirometry at baseline were excluded from this analysis, as it may not have been possible to accurately label them bronchodilator responsive or not. The remaining patients were subsequently grouped into two cohorts on the basis of their response to bronchodilator as measured by change in FEV 1 at baseline spirometry. Those patients in whom the FEV 1 improved by at least 12% and at least 200 mL (both conditions being required) were deemed to have met the commonly accepted definition of bronchodilator reversibility 15 and were aggregated in Group 1 (reversible). Those patients not meeting that criterion were called Group 2 (fixed).
Procedure
BT was performed by experienced bronchoscopists, trained in using the Alair Bronchial Thermoplasty System (Boston Scientific, Sydney, Australia). The Olympus BF-Q190 bronchoscope (Olympus Medical Systems, Tokyo, Japan) was used, and procedures were conducted according to the previously published technique. 16 All bronchoscopies were performed under general anaesthesia. The number of radiofrequency actuations delivered was recorded for each patient. Prednisolone was prescribed for 3 days prior, and continued for 3 days after each BT procedure. All patients were electively admitted to hospital for the night immediately following treatment.
Outcome measures
The outcome measures used to assess clinical improvement at 6 months post BT were pre-specified as follows: (i) ACQ-5, (ii) daily short-acting reliever usage in puffs per day, (iii) the number of oral corticosteroid requiring exacerbations in the previous 6 months, (iv) the requirement for maintenance daily oral prednisolone and (v) the FEV 1 pre-and post-bronchodilator (L). The 6-month time point for re-evaluation was chosen so as to minimize the loss of follow-up patient data over time, given that some patients were referred from regional areas of Australia.
Statistical analysis
SPSS version 24 (IBM Corporation, New York, USA) was used for all statistical analyses. Grouped data refers to all patients and is reported throughout as mean AE SD. A paired t-test was used for paired sets of pre-and post-data, whilst an unpaired t-test was used to compare groups. A Fisher's exact test was used to compare categorical data where appropriate. Statistical significance was taken throughout as P < 0.05 for a twotailed test.
RESULTS
Participants
A total of 49 patients underwent BT during the study period at the three institutions, and all were available for inclusion. Of these patients, seven were excluded as they did not meet the inclusion criterion of having airflow obstruction (FEV 1 /FVC ratio < 70%) at baseline. This left a group of 42 participants for analysis, 20 males and 22 females. Follow-up data were available for every participant.
Each included patient met the ERS/ATS definition for severe asthma. Specifically, all patients (100%) had baseline ACQ-5 scores >1.5; 35 patients (83%) had been prescribed at least two prednisolone courses in the previous year; and 40 patients (95%) demonstrated a baseline prebronchodilator FEV 1 < 80% predicted. The mean patient age was 57.2 AE 12.4 years. The mean BMI was 30.2 AE 6.8 kg/m 2 . The mean baseline ACQ-5 was 3.2 AE 1.0. Thirty-three patients were neversmokers and only four patients had a pack-year history of greater than 10. There were no current smokers. All patients had been prescribed high doses of inhaled corticosteroids, mean beclomethasone equivalent dose of 2062 AE 700 μg daily. Twenty-three patients (55%) were taking maintenance oral prednisolone, mean dose 13.6 AE 8.3 mg. All patients (100%) were using both long-acting beta 2 agonists and long-acting muscarinic antagonists. Despite this treatment, patients required an average of 8.9 AE 6.3 salbutamol puffs daily for rescue reliever therapy. The mean baseline IgE was 183 AE 214 IU/mL, and the mean absolute blood eosinophil level was 430 AE 310 cells/μL. At baseline, eight patients were being treated with omalizumab, each having been on this treatment for the previous 12 months. This treatment was continued throughout the study. No patients were initiated on a monoclonal antibody during the study.
The baseline prebronchodilator FEV 1 was 56.0 AE 16.4% predicted. The mean forced expiratory ratio was 53.1 AE 11.1%. The baseline KCO was 100.1 AE 17.2% predicted. The mean improvement in FEV 1 after 400 μg inhaled salbutamol was 14.4 AE 15.0% but the distribution was skewed to the right, as the median was 9.6 (interquartile range: 4.2-24.1).
Procedure
The total number of radiofrequency activations delivered per patient averaged 199 AE 59. One patient required treatment in the intensive care for an asthma exacerbation immediately after the procedure, and made a complete recovery. One patient was readmitted to hospital with radiologically proven right upper lobe pneumonia 6 days after upper lobe treatment. Intravenous antibiotics were prescribed and the patient was discharged on the fourth hospital day, without further incident. One patient, on two occasions, developed lobar collapse after BT, and each time required an additional bronchoscopic procedure for suction and airway clearance. There were no other adverse events.
Outcomes
The responses to treatment for the 42 patients are shown in Table 1 , which compares the six outcome measures at 6 months with baseline. Significant improvements were observed in ACQ-5, exacerbation frequency and requirement for reliever medication. The mean improvement in ACQ-5 of 1.5 is substantive at three times the minimal clinically significant change. Of the 23 patients requiring maintenance oral corticosteroids at baseline, 13 had been weaned completely at 6 months, and of the remaining 10 patients, 8 were taking smaller doses than at baseline.
Cohorts
Of the 42 patients, 18 met the definition used for bronchodilator reversibility and these patients were assigned to Group 1 (reversible airflow obstruction). The other 24 patients were assigned to Group 2 (fixed airflow obstruction). In Table 2 , the baseline characteristics of these two groups are presented and compared. The two groups were similar in most respects. However, as would be expected, the post-bronchodilator FEV 1 was significantly greater in the group of patients with reversible airflow obstruction.
The responses to treatment in the two cohorts were then evaluated. Table 3 shows the mean difference, comparing before BT with after BT, for each outcome parameter, subdivided by cohort. The responses of individual patients to BT are presented graphically in Figure S1 (Supplementary Information). The mean differences in responses between the two groups were then compared statistically. The fixed airflow obstruction group responded to BT equally well as the reversible group when compared by improvements in ACQ-5, reliever medication use, exacerbation frequency and the weaning of oral corticosteroids. In both groups, the post-bronchodilator FEV 1 was unaltered by BT. In Group 1 (reversible), BT did improve the prebronchodilator FEV 1 from 1.61 AE 0.62 at baseline to 1.85 AE 0.7 at follow-up (paired t-test, P = 0.038), or 15%. This effect was not observed in Group 2.
DISCUSSION
This group of 42 patients with severe asthma responded positively to BT with substantive improvements 6 months after treatment in ACQ-5, exacerbation frequency, reliever medication usage and the need for maintenance oral corticosteroids.
It is clear, however, that the presence or absence of bronchodilator reversibility in FEV 1 at baseline had no influence on the outcomes from BT in this study. Patients with apparently fixed airflow obstruction, as measured by spirometry, responded equally well to treatment as did their counterparts with more variable airflow obstruction. This answers a commonly asked clinical question about the suitability of this type of asthmatic for BT, and it is encouraging news for this group of patients who generally have fewer treatment options available to them.
Exactly why this should be the case is an intriguing question. The understanding of airway diseases by evaluation of FEV 1 is deeply rooted in respiratory medicine. However, in most studies of BT, patients exhibit significant clinical improvement without any improvement in FEV 1. 17-19 This suggests that we may have been looking in the wrong place in attempting to understand how BT works. It is well established that spirometry predominantly measures airway resistance in the larger airways. 20, 21 Therefore, it is possible that with BT, changes may be taking place in the peripheral airways, often referred to as the silent zone of the lung. Although these airways have a small (<2 mm) diameter, they contribute only 10% of the total airway resistance, as they constitute the bulk of the cross-sectional area of the lung. More sophisticated techniques, such as multiple-breath nitrogen washout, impedance oscillometry and functional lung imaging are required to evaluate changes in these peripheral airways, and, as yet, we do not have this data in relation to BT. However, in a mathematical model of the lung derived from human lung specimens, the effects of reducing the airway smooth muscle in the central airways by 75% has been simulated. This model demonstrated that changes to the structure of the central airways resulted in reopening of closed small airways and improved homogeneity of ventilation. 22 If the major effect of BT was to open closed peripheral airways, then this would explain why the presence or absence of a bronchodilator response in FEV 1 was immaterial in predicting response.
In this study, it is recognized that the sample sizes of the two cohorts are modest, and it is possible that, in a larger patient group, some differences in responses between the two cohorts may become apparent that we were unable to detect. Nevertheless, the current study is certainly sufficient to demonstrate that patients with fixed airflow obstruction respond to BT, and can be considered suitable candidates for this treatment.
In patients with severe asthma, the presence or absence of variable airflow obstruction as measured by spirometry does not appear to influence outcomes from BT. Patients with fixed airflow obstruction appear to respond to treatment equally well.
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